CADL (Candel Therapeutics) Beginning Cash Position: $120.15 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CADL Candel Therapeutics Inc CADL
30 GF Score
Price $10.17
! 3 Warning Signs
View Full Analysis

What is Candel Therapeutics Beginning Cash Position?

Candel Therapeutics CADL +7.38% 30 Beginning Cash Position is $120.15 Mil as of Mar. 2026. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Candel Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $120.15 Mil.

Candel Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($100.95 Mil) to Dec. 2025 ($87.23 Mil) but then increased from Dec. 2025 ($87.23 Mil) to Mar. 2026 ($120.15 Mil).

Candel Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($70.32 Mil) to Dec. 2024 ($35.68 Mil) but then increased from Dec. 2024 ($35.68 Mil) to Dec. 2025 ($102.92 Mil).

Candel Therapeutics Beginning Cash Position Related Terms

Candel Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Candel Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Candel Therapeutics Beginning Cash Position Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 35.32 83.07 70.32 35.68 102.92

Candel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.92 92.43 100.95 87.23 120.15
CADL
30GF Score
Candel Therapeutics Inc CADL
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Candel Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $120.15 Mil mean?
Candel Therapeutics (CADL) has a Beginning Cash Position of $120.15 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Candel Therapeutics and its competitors.
Is Candel Therapeutics' Beginning Cash Position too high?
Candel Therapeutics' current Beginning Cash Position is $120.15 Mil. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' Beginning Cash Position compare to AURA and RIGL?
Candel Therapeutics' Beginning Cash Position of $120.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current Beginning Cash Position is $120.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current Beginning Cash Position of $120.15 Mil. The current Beginning Cash Position is $120.15 Mil. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current Beginning Cash Position is $120.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Candel Therapeutics Business Description

Address 117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score

Get the complete analysis for CADL

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.17
Price